SLQT

SelectQuote Inc

Add to Watchlist

Advanced Chart

2.590

+0.76(41.530%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.750

Open

2.230

VWAP

2.53

Vol

23.18M

Mkt Cap

447.35M

Low

2.180

Amount

58.52M

EV/EBITDA(TTM)

8.17

Total Shares

169.16M

830.38M

EV/OCF(TTM)

18.13

P/S(TTM)

0.22

SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises the SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expense, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q2

FY2026Q1

458.82M

+12.41%

533.79M

+10.96%

335.25M

+14.71%

Estimates Revision

The market is revising Downward the revenue expectations for SelectQuote, Inc. (SLQT) for FY2025, with the revenue forecasts being adjusted by -0.38% over the past three months. During the same period, the stock price has changed by 16.14%.

Revenue Estimates for FY2025

Revise Downward

-0.38%

In Past 3 Month

Stock Price

Go Up

+16.14%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast SLQT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLQT is 5.25 USD with a low forecast of 2.75 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

2 Hold

0 Sell

Moderate Buy

Current: 2.590

Low

2.75

Averages

5.25

High

7.00

Current: 2.590

Low

2.75

Averages

5.25

High

7.00

Jefferies

Hold

initiated

$2.75

2025-05-21

Reason

Jefferies

Price Target

$2.75

2025-05-21

initiated

Hold

Reason

Jefferies initiated coverage of SelectQuote with a Hold rating and $2.75 price target. The company's "important position" in the Medicare Advantage supply chain, combined with a single marketing engine, is delivering growth of both Medicare Advantage policies and Health services, like SelectRx, the analyst tells investors in a research note. However, Jefferies says SelectRx's strategic redirect to even higher acuity members, the recent Department of Justice lawsuit, "suboptimal" cash conversion, and a "complicated balance sheet" keep it on the sidelines.

RBC Capital

Ben Hendrix

Hold

Reiterates

2024-11-22

Reason

RBC Capital

Ben Hendrix

Price Target

2024-11-22

Reiterates

Hold

Reason

RBC Capital

Ben Hendrix

Hold

Reiterates

2024-10-29

Reason

RBC Capital

Ben Hendrix

Price Target

2024-10-29

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for SelectQuote Inc (SLQT.N) is -22.10, compared to its 5-year average forward P/E of -5.67. For a more detailed relative valuation and DCF analysis to assess SelectQuote Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.67

Current PE

-22.10

Overvalued PE

19.41

Undervalued PE

-30.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

2.29

Current EV/EBITDA

6.60

Overvalued EV/EBITDA

54.89

Undervalued EV/EBITDA

-50.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.07

Current PS

0.19

Overvalued PS

2.41

Undervalued PS

-0.27